Purification Process of a Recombinant Human Follicle Stimulating Hormone Biosimilar (Primapur®) to Yield a Pharmaceutical Product with High Batch-to-Batch Consistency [PDF]
Pharmaceutics, 2022 Recombinant human follicle stimulating hormone (r-hFSH) is widely used for infertility treatment and is subject to the development of biosimilars. There are different purification strategies that can yield r-hFSH of pharmaceutical quality from Chinese hamster ovary cell culture broth.
Maria Sinegubova +6 more
openaire +3 more sources
Has The Era Of Slow Growth For Prescription Drug Spending Ended? [PDF]
, 2016 In the period 2005–13 the US prescription drug market grew at an average annual pace of only 1.8 percent in real terms on an invoice price basis (that is, in constant dollars and before manufacturers’ rebates and discounts). But the growth rate increased
Aitken, M. +4 more
core +1 more source
Biosimilar tenecteplase versus alteplase in acute ischemic stroke: A real world study
Annals of Indian Academy of Neurology, 2023 Background and Purpose: There is an unmet need for a more effective thrombolytic agent in acute ischemic stroke (AIS) management. Various studies and meta-analysis suggest tenecteplase (TNK) as non-inferior over alteplase (rTPA).
Ayush Mohan +11 more
doaj +1 more source
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. [PDF]
, 2019 PURPOSE: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.
Bohlius, Julia +12 more
core +3 more sources
Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
Acta Médica Portuguesa, 2018 Introduction: Biosimilars are highly similar copies of previously approved original biologic medicines. Their introduction on the market may yield cost reduction.
Alexandra Azevedo +3 more
doaj +1 more source
Medicines under additional monitoring in the European Union [PDF]
Farmacia Hospitalaria, 2019 Objective: The objective of this study was to analyse the characteristics of medicines subject to additional monitoring. We assessed the following aspects: the criteria applied to approve a medicine as being subject to additional monitoring; the ...
Esther Salgueiro +5 more
doaj +1 more source
Pharmacy Practice, 2021 Background: Recent approvals for novel agents such as the small molecule Janus kinase inhibitors (JAKi), combined with the advent of biosimilars has widened the gamut of available therapeutic options in the treatment of rheumatoid arthritis (RA).
Denis Choquette +6 more
doaj +1 more source
Biosimilar infliximab introduction into the gastro-enterology care pathway in a large acute Irish teaching hospital: a story behind the evidence [PDF]
, 2018 Background and aim: Biosimilar medicines are not considered exact replicas of originator biological medicines. As a result, prescribers can be hesitant to introduce such medicines into the clinical setting until evidence surfaces confirming their safety ...
Byrne, Stephen +5 more
core +1 more source
Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry [PDF]
DARU Journal of Pharmaceutical Sciences, 2012 In 1980s, medicines produced through recombinant DNA technology created a novel opportunity for management of several debilitating and life threatening diseases. However, these medicines are very expensive and therefore not affordable for many patients especially those living in low resourced countries.
openaire +2 more sources
4CPS-008 Impact of pharmaceutical interview in patient acceptance of insulin glargine’s biosimilar 100UI/ml [PDF]
Section 4: Clinical Pharmacy Services, 2019 Background The insulin glargine’s biosimilar (IB) has been marketed since 2016, and is far less costly for the healthcare system, but their prescription is not yet predominant. To prescribe a biosimilar, the patient must be informed on what constitutes a biosimilar and must provide his agreement.
M Malassigné +5 more
openaire +1 more source